KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $245.5 million.

  • Emergent BioSolutions' Cash & Equivalents rose 63.78% to $245.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.5 million, marking a year-over-year increase of 63.78%. This contributed to the annual value of $99.5 million for FY2024, which is 10.92% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Revenue - Interest and Investment Income of $366.2 million as of Q3 2010, which was up 5.93% from $345.7 million recorded in Q2 2010.
  • Emergent BioSolutions' Cash & Equivalents' 5-year high stood at $642.6 million during Q4 2022, with a 5-year trough of $69.7 million in Q2 2024.
  • In the last 3 years, Emergent BioSolutions' Cash & Equivalents had a median value of $111.7 million in 2023 and averaged $161.6 million.
  • In the last 5 years, Emergent BioSolutions' Cash & Equivalents tumbled by 82.62% in 2023 and then skyrocketed by 283.50% in 2025.
  • MRQ analysis of 5 years shows Emergent BioSolutions' Cash & Equivalents stood at $576.1 million in 2021, then increased by 11.54% to $642.6 million in 2022, then tumbled by 82.62% to $111.7 million in 2023, then fell by 10.92% to $99.5 million in 2024, then surged by 146.73% to $245.5 million in 2025.
  • Its Cash & Equivalents stands at $245.5 million for Q3 2025, versus $267.3 million for Q2 2025 and $149.1 million for Q1 2025.